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LETTER TO THE EDITOR
Successful Tocilizumab Treatment for Scleritis
Huub J. Poelman1, Paul L.A. Van Daele2, and A Rothova1
1Department of Ophthalmogy, Erasmus MC, Rotterdam, The Netherlands and 2Internal Medicine, Section
Allergology & Clinical Immunology, Erasmus MC, Rotterdam, The Netherlands
ABSTRACT
Purpose: To present a rare case of scleritis associated with a prior diagnosis of giant cell arteritis (GCA) that was
unresponsive to glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), methotrexate, and azathiopr-
ine, but reached and maintained a full remission with tocilizumab.
Observations: A 62-year-old Caucasian female presented with scleritis and headache. Four years earlier, the
patient was diagnosed with GCA. Treatment with topical and systemic NSAIDs, prednisone and diverse
disease-modifying antirheumatic drugsonly had a partial effect on the scleritis whilst the arthralgia and
headaches increased. Despite the absence of laboratory evidence of active GCA, tocilizumab was started and
the scleritis and headaches disappeared within several days. Prednisone could be fully tapered within 3
months and to date, 12 months after the start of tocilizumab, the patient has maintained a sustained remission.
Conclusions: Our patient demonstrates that tocilizumab might represent a therapeutic option for scleritis, and its
further evaluation for this severe ocular disease is worthwhile.
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Scleritis represents a severe ocular disorder, which is
commonly treated with nonsteroidal anti-
inflammatory drugs (NSAIDs) or disease-modifying
antirheumatic drugs (DMARDs), whilst glucocorti-
coids are frequently used in the acute stage of the
disease. When these therapies fail, the next step in
treatment is still unclear.
Giant cell arteritis (GCA), or temporal arteritis, is an
inflammatory disease of the large- and medium-sized
arteries, most commonly involving the branches of the
carotid arteries. Inflammation of the artery wall leads to
intimal hyperplasia and lumen occlusion and can cause
ischemic complications. The most common ocular man-
ifestation of GCA is the involvement of the ophthalmic
artery, resulting in arteritic anterior ischemic optic neu-
ropathy with permanent visual loss. Scleritis represents
a rare complication of GCA.1,2
Recently, beneficial results of treatment of GCA
were reported with a recombinant humanized anti-
interleukin-6 (IL-6) receptor monoclonal antibody
(tocilizumab), but whether this treatment approach
would be effective for scleritis is not known.3,4
In this report, we describe a case of scleritis in
a patient with a prior biopsy-proven GCA that was
unresponsive to glucocorticoids, methotrexate, and
azathioprine, but reached and maintained a full
remission with tocilizumab.
CASE REPORT
A 62-year-old Caucasian female presented with tem-
poral headaches and red painful eyes. She also had
general complaints of fatigue and painful joints. Four
years before the scleritis onset, the patient was diag-
nosed with GCA with a positive biopsy of temporal
artery and treated with systemic prednisone for two
years. At the time of scleritis onset, she used no sys-
temic prednisone.
On external examination, a bilateral purple-red injec-
tion of the sclera in the anterior part of the eyeballs was
seen. Further ophthalmological examinationwaswithin
the normal limits with the exception of elevated intrao-
cular pressure (IOP; OD 29 and OS 22 mmHg).
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Laboratory results showed inflammatory para-
meters to be within the normal limits. All additional
examinations for autoimmune disorders were nega-
tive (Table 1). There were no abnormalities suggestive
for sarcoidosis (chest radiologic examination, serum
angiotensin converting enzyme, and serum interleu-
kin 2 receptor were within the normal limits).
The patient was initially treated with topical anti-
inflammatory and IOP-lowering medications with
the addition of systemic indomethacin (150 mg/
day), which had an insufficient effect on her scleritis
and had to be stopped because of mouth ulcers.
Treatment with methotrexate (MTX, initial dose
15mg/week) and systemic prednisone (initial dose
30 mg/day) was started; however, MTX had to be
stopped after 4 months because of nausea and
arthralgia. MTX was switched to azathioprine
(100 mg/day) and topical cyclosporine-A ointment
was added to topical NSAIDs and steroids.
A partial effect on scleritis was observed within
several weeks, but after 6 months, the patient
stopped azathioprine because she did not feel well
and had increasing complaints of arthralgia,
although arthritis was never documented. Patient
increased her prednisone dosage to 60 mg/day
because of recurrence of scleritis activity and extre-
mely painful eyes, which had a good effect.
A gradual withdrawal of systemic prednisone was
attempted, but with the dosage below 40 mg/day,
severe scleritis recurred and the patient complained
of intense eye pain and temporal headaches.
Several treatment options were discussed. Despite
the absence of laboratory evidence of active GCA,
tocilizumab subcutaneous injections were chosen
(162 mg/0.9 mL once a week) because of the patients’
own desire and previously reported beneficial effect
in GCA and other autoimmune diseases. With tocili-
zumab and prednisone 40 mg, scleritis and temporal
headaches gradually disappeared within several days
and prednisone could be fully tapered within 3
months. To date, 12 months after the start of
tocilizumab, the patient has maintained a sustained
remission without any adverse effects.
DISCUSSION
Scleritis is commonly associated with various sys-
temic autoimmune diseases and is extremely difficult
to treat. In the blood of patients with active scleritis,
high levels of IL-22 were reported.5 IL-22 (among
others) is being produced by Th17-positive cells.
Remarkably, increased Th17 cells were observed in
the blood of patients with active scleritis.
Tocilizumab blocks IL-6 signaling and inhibits differ-
entiation of naïve T cells into Th17 cells, which might
explain its efficacy.
In our patient, it was not feasible to conclude defi-
nitively whether GCA was active at scleritis onset.
Though her values of CRP and ESR were within the
normal limits, this does not entirely exclude the recur-
rence of GCA. The temporal headaches with the his-
tory of GCA make a recurrence of GCA a possibility.
Whether or not the scleritis was related to prior GCA,
we point out a beneficial and prolonged effect of
tocilizumab on scleritis, refractory to diverse
DMARDs and systemic prednisone. Tocilizumab
might represent a therapeutic option for scleritis and
its further evaluation for this severe ocular disease is
worthwhile.
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TABLE 1. Laboratory examinations.
Blood test Result Normal range
C-reactive protein (CRP) 1.4 mg/L (<10)
Erythrocyte sedimentation rate (ESR/BSE) 7 mm/h (0–30)
White blood cell count 6.4 10^9/L (3.5–10.0)
Angiotensine converting enzyme (ACE) 42.3 U/L (12–68)
Human leukocyte antigens B27 (HLA-B27 Negative
Antinuclear antibodies (ANA) Negative
Cytoplasmic antineutrophil cytoplasmic antibodiesc (ANCA) Negative
Rheumatoid factor IgM 2.1 IU/mL (<3.5)
Anti-cyclic citrullinated peptides <0.4 U/mL (<4.0)
Anti-Sjögren syndrome-related antigen A (Anti SS-A 52/60) Negative
Anti-Sjögren syndrome-related antigen B (Anti SS-B) Negative
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PATIENT CONSENT
Consent to publish this case report was not obtained.
This report does not contain any personal information
that could lead to the identification of the patient.
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